Evidence map›Paper›PMID 36835121›Full record

ArticleInternational journal of molecular sciences2023

The Relationship between Iron and LRRK2 in a 6-OHDA-Induced Parkinson's Disease Model.

Ruru Jia, Yanling Liu, Ke Shuai, Cheng Zhou, Lei Chen, Li Zhu, Xiao-Mei Wu

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Synthetic Cyclic CAntioxidants (Basel, Switzerland) · 2026
    Article
  3. Article
  4. Synthetic Cyclic CAntioxidants (Basel, Switzerland) · 2025
    Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Ruru JiaLaboratory of Hypoxic Biomedicine, Institute of Special Environmental Medicine, Co-Innovation Center of Neuroregeneration, Nantong University, 9 Seyuan Road, Nantong 226019, China.
Yanling LiuLaboratory of Hypoxic Biomedicine, Institute of Special Environmental Medicine, Co-Innovation Center of Neuroregeneration, Nantong University, 9 Seyuan Road, Nantong 226019, China.
Ke ShuaiLaboratory of Hypoxic Biomedicine, Institute of Special Environmental Medicine, Co-Innovation Center of Neuroregeneration, Nantong University, 9 Seyuan Road, Nantong 226019, China.
Cheng ZhouLaboratory of Hypoxic Biomedicine, Institute of Special Environmental Medicine, Co-Innovation Center of Neuroregeneration, Nantong University, 9 Seyuan Road, Nantong 226019, China.
Lei ChenLaboratory of Hypoxic Biomedicine, Institute of Special Environmental Medicine, Co-Innovation Center of Neuroregeneration, Nantong University, 9 Seyuan Road, Nantong 226019, China.
Li ZhuLaboratory of Hypoxic Biomedicine, Institute of Special Environmental Medicine, Co-Innovation Center of Neuroregeneration, Nantong University, 9 Seyuan Road, Nantong 226019, China.
Xiao-Mei WuLaboratory of Hypoxic Biomedicine, Institute of Special Environmental Medicine, Co-Innovation Center of Neuroregeneration, Nantong University, 9 Seyuan Road, Nantong 226019, China.
Nantong University · CN

Funding

National Natural Science Foundation of China 81971131Science and Technology Innovation Project of Nantong MS12017014-7
6 · The paper itself

Abstract

The pathogenesis of Parkinson's disease (PD) is very complex and still needs further exploration. Leucine-rich repeat kinase 2 (LRRK2) is associated with familial PD in mutant forms and sporadic PD in the wild-type form. Abnormal iron accumulation is found in the substantia nigra of PD patients, but its exact effects are not very clear. Here, we show that iron dextran exacerbates the neurological deficit and loss of dopaminergic neurons in 6-OHDA lesioned rats. 6-OHDA and ferric ammonium citrate (FAC) significantly increase the activity of LRRK2 as reflected by the phosphorylation of LRRK2, at S935 and S1292 sites. 6-OHDA-induced LRRK2 phosphorylation is attenuated by the iron chelator deferoxamine, especially at the S1292 site. 6-OHDA and FAC markedly induce the expression of pro-apoptotic molecules and the production of ROS by activating LRRK2. Furthermore, G2019S-LRRK2 with high kinase activity showed the strongest absorptive capacity for ferrous iron and the highest intracellular iron content among WT-LRRK2, G2019S-LRRK2, and kinase-inactive D2017A-LRRK2 groups. Taken together, our results demonstrate that iron promotes the activation of LRRK2, and active LRRK2 accelerates ferrous iron uptake, suggesting that there exists an interplay between iron and LRRK2 in dopaminergic neurons, providing a new perspective to uncover the underlying mechanisms of PD occurrence.

Indexed as

IronLeucine-Rich Repeat Serine-Threonine Protein Kinase-2Parkinson DiseaseAnimalsDisease Models, AnimalDopaminergic NeuronsMutationOxidopamineRatsSubstantia NigraIronLeucine-Rich Repeat Serine-Threonine Protein Kinase-2LRRK2 protein, ratOxidopamineapoptosisdopaminergic neuronironLRRK2Parkinson’s disease

Identifiers

PMID36835121
PMCPMC9964371
OpenAlexW4320496621

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.